New blood test that detects cancer by measuring glycosidase enzyme activity with volatile ethanol probes.
Evaluation of a New Method for Detecting Cancer Pathologies by Measuring the Activity of Different Glycosidases in Plasma in Patients With Localized Cancer - Pilot Study: B-GLUCANCER2
This pilot will test whether a blood test using volatile probes that release ethanol can detect localized breast, lung, and pancreatic cancers in patients scheduled for surgery.
Quick facts
| Phase | Early Phase 1 |
|---|---|
| Study type | Interventional |
| Enrollment | 220 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Poitiers University Hospital Academic / other |
| Locations | 1 site (Poitiers) |
| Trial ID | NCT07236177 on ClinicalTrials.gov |
What this trial studies
Researchers will add a panel of volatile organic compound probes to small plasma samples; each probe is designed to be cleaved by a specific glycosidase and release a labeled ethanol isotope that can be detected in the gas phase. The trial enrolls three patient groups with confirmed, untreated localized breast, lung, or pancreatic cancer and a larger control group without cancer. Cancer patients provide two 5 mL plasma samples (one before and one after surgery) while healthy volunteers give a single 5 mL sample. The primary objective is to compare glycosidase activity levels measured in plasma between the cancer groups and controls to explore diagnostic and prognostic signals.
Who should consider this trial
Good fit: Ideal participants are adults with confirmed, untreated localized breast, lung, or pancreatic cancer who are scheduled for initial surgical treatment, as well as healthy adult volunteers for the control group.
Not a fit: Patients with metastatic disease, those already receiving cancer therapy, minors, pregnant or breastfeeding women, and people under legal protection are excluded and unlikely to receive benefit from this pilot.
Why it matters
Potential benefit: If successful, this could become a simple, non‑invasive blood test to help detect and monitor localized breast, lung, and pancreatic cancers earlier or guide surgical decision making.
How similar studies have performed: This precise technique—using exogenous volatile probes that liberate ethanol isotopes to report glycosidase activity—is novel and largely untested in humans, although other enzyme‑based blood biomarkers have been explored.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Group 1: 40 patients with definitively diagnosed, untreated, localized solid breast cancer referred for initial surgical treatment. Group 2: 40 patients with definitively diagnosed, untreated, localized solid lung cancer referred for initial surgical treatment. Group 3: 40 patients with definitively diagnosed, untreated, localized solid pancreatic cancer referred for initial surgical treatment. Group 4: 100 control patients with no cancer diagnosis or history of solid or hematological cancer. Exclusion Criteria: * Refusal to participate in the research. * Patients benefiting from enhanced protection, namely: minors, pregnant/breastfeeding women, persons deprived of their liberty by a judicial or administrative decision, persons staying in a social care facility, adults under legal protection Specific criteria for groups 1, 2, and 3: * Cancer patients undergoing oncological treatment. * Cancer not proven by anatomopathological examination.
Where this trial is running
Poitiers
- C.H.U. Poitiers — Poitiers, France (Recruiting)
Study contacts
- Study coordinator: Sheik Emambux, MD PhD
- Email: sheik.emambux@chu-poitiers.mssante.fr
- Phone: +33549444279
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.